Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Green Cross Holdings Corporation is a South Korean healthcare conglomerate operating pharmaceutical manufacturing, vaccine production, and plasma-derived biotherapeutics. The company holds a dominant position in Korea's blood plasma fractionation market and operates a vertically integrated model from R&D through commercial distribution. Recent 18.5% revenue growth reflects expansion in biosimilars and specialty therapeutics, though negative cash flow indicates heavy investment in manufacturing capacity and clinical pipelines.
Green Cross generates revenue through vertically integrated biopharmaceutical operations, controlling plasma collection centers, fractionation facilities, and distribution networks primarily in South Korea. The company benefits from high barriers to entry in plasma fractionation (regulatory complexity, capital intensity requiring $200M+ facilities, 18-24 month production cycles) and long-term supply contracts with hospitals. Pricing power derives from limited domestic competition in plasma therapeutics and reimbursement stability under Korea's National Health Insurance system. Biosimilar portfolio targets high-value biologics post-patent expiry, capturing 30-40% discounts to reference products while maintaining 40-50% gross margins.
Biosimilar approval milestones and market share capture in key therapeutic areas (oncology, immunology)
Plasma collection volumes and fractionation yield rates (recovery rates of 85-90% are industry standard)
Korean National Health Insurance reimbursement rate decisions affecting drug pricing
Clinical trial readouts for proprietary pipeline assets in Phase II/III development
Capacity utilization rates at fractionation facilities and manufacturing expansion timelines
Biosimilar margin compression as competition intensifies in key molecules - first-wave biosimilars now face 3-5 competitors in major markets, driving 20-30% price erosion
Regulatory changes to Korean pharmaceutical pricing and reimbursement policies - government cost containment initiatives could pressure margins on established products
Plasma supply constraints and rising donor compensation costs - US plasma accounts for 70% of global supply, and donor fees have increased 40-50% since 2020
Global plasma fractionators (CSL Behring, Takeda, Grifols) expanding into Asian markets with superior scale and diversified product portfolios
Biosimilar competition from larger players (Samsung Bioepis, Celltrion) with greater manufacturing scale and global commercialization capabilities
Emerging cell and gene therapies potentially displacing traditional plasma-derived treatments for hemophilia and immunodeficiencies
Negative free cash flow of $95.9B (13% FCF yield) indicates ongoing cash consumption requiring external financing or asset sales
Current ratio of 1.18x provides limited liquidity buffer if operating cash flow remains negative - working capital management critical
Debt/equity of 0.79x is manageable but rising interest rates increase debt service burden during investment phase before new capacity generates returns
low - Healthcare demand is largely non-discretionary with plasma therapeutics treating chronic conditions (immunodeficiencies, hemophilia) requiring continuous therapy regardless of economic conditions. Korean National Health Insurance provides ~97% population coverage, insulating demand from consumer spending cycles. However, elective procedures and preventive vaccines show modest correlation to GDP growth. The 18.5% revenue growth during recent period suggests company-specific expansion rather than cyclical tailwinds.
Rising interest rates create moderate headwinds through higher financing costs on the 0.79x debt/equity ratio and pressure valuation multiples for growth-oriented biotech stocks. The $42.4B capex program (likely facility expansion and equipment) may face higher borrowing costs if debt-financed. However, healthcare stocks typically trade on earnings growth and pipeline value rather than yield, reducing rate sensitivity versus REITs or utilities. Current negative free cash flow makes the company more vulnerable to tightening credit conditions.
Moderate exposure to credit conditions. Biopharmaceutical manufacturing requires substantial upfront capital ($150-300M for plasma fractionation facilities) typically financed through debt or equity raises. Tighter credit markets could delay expansion plans or increase cost of capital for the current investment cycle. However, established revenue base and government-backed healthcare reimbursement provide stable cash flows supporting creditworthiness. Customer credit risk is minimal given hospital/institutional buyers and government reimbursement mechanisms.
growth - The 18.5% revenue growth, biosimilar pipeline expansion, and negative FCF profile attract growth investors willing to accept near-term cash consumption for market share gains and capacity buildout. The negative net margin and ROE indicate the company is in investment mode rather than harvest mode, typical of growth-stage biotech. However, recent 15% six-month decline suggests momentum investors have rotated out, leaving fundamental growth investors focused on 2027-2028 profitability inflection.
moderate-to-high - Biotech stocks typically exhibit 25-35% annualized volatility driven by binary clinical/regulatory events, though established commercial operations provide some stability. The 8.8% one-year return versus -15% six-month return indicates significant intra-year swings. Korean small-cap healthcare names face additional volatility from limited liquidity and foreign investor flows. Beta likely 1.2-1.5x versus broader Korean equity market.
